Mumbai, Apr 10 : Pharma major Lupin Limited (Lupin) announced the launch of Fluoxetine Tablets USP, 60mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin's Fluoxetine Tablets USP, 60mg, is the generic version of Alvogen Group Holdings 3 LLC's Fluoxetine Tablets, 60mg, the company said in a statement here. It is indicated in the treatment of Major Depressive Disorder (MDD) and Obsessive Compulsive Disorder (OCD)
It is also indicated for Panic disorder, with or without agoraphobia. Fluoxetine Tablets, 60mg, had annual sales of around USD 41 million in the US (IQVIA MAT February, 2019). (UNI)